CN107666906A - 用于治疗癌症的方法 - Google Patents

用于治疗癌症的方法 Download PDF

Info

Publication number
CN107666906A
CN107666906A CN201680032355.6A CN201680032355A CN107666906A CN 107666906 A CN107666906 A CN 107666906A CN 201680032355 A CN201680032355 A CN 201680032355A CN 107666906 A CN107666906 A CN 107666906A
Authority
CN
China
Prior art keywords
cancer
compound
paclitaxel
formula
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680032355.6A
Other languages
English (en)
Chinese (zh)
Inventor
C·J·李
W·李
Y·李
M·J·黑特罗恩
高媛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Bio Pharmaceutical Co Ltd
Original Assignee
Boston Bio Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Bio Pharmaceutical Co Ltd filed Critical Boston Bio Pharmaceutical Co Ltd
Publication of CN107666906A publication Critical patent/CN107666906A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680032355.6A 2015-04-17 2016-04-18 用于治疗癌症的方法 Pending CN107666906A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562149349P 2015-04-17 2015-04-17
US62/149,349 2015-04-17
US201662280947P 2016-01-20 2016-01-20
US62/280,947 2016-01-20
PCT/US2016/028177 WO2016168856A1 (en) 2015-04-17 2016-04-18 Methods for treating cancer

Publications (1)

Publication Number Publication Date
CN107666906A true CN107666906A (zh) 2018-02-06

Family

ID=55854799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680032355.6A Pending CN107666906A (zh) 2015-04-17 2016-04-18 用于治疗癌症的方法

Country Status (16)

Country Link
US (1) US20180085341A1 (enExample)
EP (1) EP3283069A1 (enExample)
JP (1) JP2018511643A (enExample)
KR (1) KR20180006918A (enExample)
CN (1) CN107666906A (enExample)
AU (1) AU2016247319A1 (enExample)
BR (1) BR112017022281A2 (enExample)
CA (1) CA2983010A1 (enExample)
EA (1) EA201792287A1 (enExample)
HK (1) HK1250944A1 (enExample)
IL (1) IL255022A0 (enExample)
MX (1) MX2017013360A (enExample)
PH (1) PH12017501879A1 (enExample)
SG (2) SG11201708504XA (enExample)
TW (1) TW201713327A (enExample)
WO (1) WO2016168856A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020074010A1 (zh) * 2018-10-12 2020-04-16 北京强新生物科技有限公司 治疗化疗难治性癌症的新联合用药方案
CN113544511A (zh) * 2019-03-05 2021-10-22 米拉索莱人文股份公司 评价受前列腺癌影响的风险的方法
CN113906298A (zh) * 2019-03-27 2022-01-07 新加坡保健服务集团有限公司 对腹膜癌扩散具有治疗意义的生物标志物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027443T2 (en) 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
JP2019506392A (ja) * 2016-01-20 2019-03-07 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP3678663A4 (en) * 2017-09-05 2021-06-02 Epizyme, Inc. POLYTHERAPY FOR CANCER TREATMENT

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036101A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
WO2014169078A2 (en) * 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002890A (zh) 2010-03-19 2013-03-27 波士顿生物医学公司 靶向癌症干细胞的新的化合物和组合物
CN103025159A (zh) 2010-03-19 2013-04-03 波士顿生物医学公司 靶向癌症干细胞的新方法
EP2681203A4 (en) 2011-03-04 2014-07-30 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd NOVEL 4,9-DIHYDROXY-NAPHTO [2,3-B] FURANS ESTERS FOR THERAPEUTIC TREATMENT OF DISEASES
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
JP2019506392A (ja) * 2016-01-20 2019-03-07 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036101A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
CN103288787A (zh) * 2007-09-10 2013-09-11 波士顿生物技术公司 新的stat3 途径抑制剂和癌症干细胞抑制剂
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
WO2014169078A2 (en) * 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020074010A1 (zh) * 2018-10-12 2020-04-16 北京强新生物科技有限公司 治疗化疗难治性癌症的新联合用药方案
CN113164438A (zh) * 2018-10-12 2021-07-23 北京强新生物科技有限公司 治疗化疗难治性癌症的新联合用药方案
CN113544511A (zh) * 2019-03-05 2021-10-22 米拉索莱人文股份公司 评价受前列腺癌影响的风险的方法
CN113906298A (zh) * 2019-03-27 2022-01-07 新加坡保健服务集团有限公司 对腹膜癌扩散具有治疗意义的生物标志物

Also Published As

Publication number Publication date
WO2016168856A1 (en) 2016-10-20
JP2018511643A (ja) 2018-04-26
IL255022A0 (en) 2017-12-31
HK1250944A1 (zh) 2019-01-18
EA201792287A1 (ru) 2018-03-30
BR112017022281A2 (pt) 2018-07-10
AU2016247319A1 (en) 2017-11-02
MX2017013360A (es) 2018-08-01
TW201713327A (zh) 2017-04-16
KR20180006918A (ko) 2018-01-19
SG10201900564WA (en) 2019-02-27
SG11201708504XA (en) 2017-11-29
EP3283069A1 (en) 2018-02-21
CA2983010A1 (en) 2016-10-20
PH12017501879A1 (en) 2018-03-05
US20180085341A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
CN107666906A (zh) 用于治疗癌症的方法
US10646464B2 (en) Methods for treating cancer
US20190231735A1 (en) Methods for treating cancer
JP2021121629A (ja) Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
WO2018005444A2 (en) Methods for treating cancer
CN107820426A (zh) 用于治疗癌症的方法
AU2019357933B2 (en) New combination solution for treating chemotherapy refractory cancer
HK40047114A (en) New combination solution for treating chemotherapy refractory cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180206

WD01 Invention patent application deemed withdrawn after publication